




Figure S1 Assessment of covariate balance before and after PSM based on SMD for variables listed in Table S1. ELNs, examined lymph nodes; N, node; PSM, propensity score matching; SMD, standardized mean deviation; T, tumor.




Figure S2 Assessment of covariate balance before and after PSM based on SMD for variables listed in Table S2. ELNs, examined lymph nodes; PSM, propensity score matching; SMD, standardized mean deviation; T, tumor.




Figure S3 Assessment of covariate balance before and after PSM based on SMD for variables listed in Table S3. ELNs, examined lymph nodes; N, node; PSM, propensity score matching; SMD, standardized mean deviation; T, tumor.




Figure S4 Assessment of covariate balance before and after PSM based on SMD for variables listed in Table S4. ELNs, examined lymph nodes; N, node; PSM, propensity score matching; SMD, standardized mean deviation; T, tumor.

Table S1 Baseline characteristics of the overall population with Siewert type II AEG

Characteristics	Unadjusted				PSM			
	Total (n=1,847)	SA (n=788)	NS (n=1,059)	P	Total (n=792)	SA (n=396)	NS (n=396)	P
Age, years	63.8±11.3	67.4±11.5	61.1±10.3	<0.001	64.4±10.6	64.5±12.1	64.4±8.8	0.89
Sex				<0.001				0.79
Male	1,499 (81.2)	594 (75.4)	905 (85.5)		641 (80.9)	322 (81.3)	319 (80.6)	
Female	348 (18.8)	194 (24.6)	154 (14.5)		151 (19.1)	74 (18.7)	77 (19.4)	
Race				0.07				0.33
White	1,621 (87.8)	676 (85.8)	945 (89.2)		680 (85.9)	345 (87.1)	335 (84.6)	
Black	80 (4.3)	42 (5.3)	38 (3.6)		40 (5.1)	21 (5.3)	19 (4.8)	
Other	146 (7.9)	70 (8.9)	76 (7.2)		72 (9.1)	30 (7.6)	42 (10.6)	
Marital status				0.02				0.81
Unmarried	514 (27.8)	242 (30.7)	272 (25.7)		223 (28.2)	113 (28.5)	110 (27.8)	
Married	1,333 (72.2)	546 (69.3)	787 (74.3)		569 (71.8)	283 (71.5)	286 (72.2)	
T stage				<0.001				0.53
T1	463 (25.1)	362 (45.9)	101 (9.5)		198 (25.0)	105 (26.5)	93 (23.5)	
T2	563 (30.5)	283 (35.9)	280 (26.4)		333 (42.0)	159 (40.2)	174 (43.9)	
T3	738 (40.0)	118 (15.0)	620 (58.5)		214 (27.0)	111 (28.0)	103 (26.0)	
T4	83 (4.5)	25 (3.2)	58 (5.5)		47 (5.9)	21 (5.3)	26 (6.6)	
N stage				<0.001				0.66
N0	796 (43.1)	492 (62.4)	304 (28.7)		363 (45.8)	189 (47.7)	174 (43.9)	
N1	696 (37.7)	186 (23.6)	510 (48.2)		271 (34.2)	130 (32.8)	141 (35.6)	
N2	253 (13.7)	72 (9.1)	181 (17.1)		109 (13.8)	55 (13.9)	54 (13.6)	
N3	102 (5.5)	38 (4.8)	64 (6.0)		49 (6.2)	22 (5.6)	27 (6.8)	
Grade				<0.001				0.99
I	126 (6.8)	78 (9.9)	48 (4.5)		42 (5.3)	20 (5.1)	22 (5.6)	
II	630 (34.1)	290 (36.8)	340 (32.1)		272 (34.3)	134 (33.8)	138 (34.8)	
III	956 (51.8)	384 (48.7)	572 (54.0)		426 (53.8)	215 (54.3)	211 (53.3)	
IV	34 (1.8)	12 (1.5)	22 (2.1)		11 (1.4)	6 (1.5)	5 (1.3)	

Unknown	101 (5.5)	24 (3.0)	77 (7.3)		41 (5.2)	21 (5.3)	20 (5.1)	
Tumor size				<0.001				0.81
>2 cm	283 (15.3)	180 (22.8)	103 (9.7)		111 (14.0)	56 (14.1)	55 (13.9)	
≥2, <4 cm	536 (29.0)	262 (33.2)	274 (25.9)		240 (30.3)	126 (31.8)	114 (28.8)	
≥4, <6 cm	400 (21.7)	150 (19.0)	250 (23.6)		185 (23.4)	90 (22.7)	95 (24.0)	
≥6 cm	309 (16.7)	119 (15.1)	190 (17.9)		157 (19.8)	73 (18.4)	84 (21.2)	
Unknown	319 (17.3)	77 (9.8)	242 (22.9)		99 (12.5)	51 (12.9)	48 (12.1)	
Surgical type				0.01				0.94
TG	522 (28.3)	198 (25.1)	324 (30.6)		199 (25.1)	100 (25.3)	99 (25.0)	
PG	1,325 (71.7)	590 (74.9)	735 (69.4)		593 (74.9)	296 (74.7)	297 (75.0)	
ELN	16.8±10.9	15.8±10.6	17.5±11.2	0.001	16.8±10.8	16.7±10.7	16.8±11.0	0.93

Data are presented as n (%) or mean ± standard deviation. AEG, adenocarcinoma of the esophagogastric junction; ELN, examined lymph nodes; N, node; NS, Neoadjuvant-based therapy combined with surgery; PG, proximal gastrectomy; PSM, propensity score matching; SA, surgery alone; TG, total gastrectomy; T, tumor.

Table S2 Baseline characteristics of patients with early-stage Siewert type II AEG

Characteristics	Unadjusted				PSM			
	Total (n=598)	SA (n=451)	NS (n=147)	P	Total (n=246)	SA (n=123)	NS (n=123)	P
Age, years	65.2±10.9	65.5±11.5	64.3±8.9	0.26	64.4±10.9	64.0±12.7	64.7±8.7	0.65
Sex				0.21				0.63
Male	470 (78.6)	349 (77.4)	121 (82.3)		195 (79.3)	96 (78)	99 (80.5)	
Female	128 (21.4)	102 (22.6)	26 (17.7)		51 (20.7)	27 (22)	24 (19.5)	
Race				0.64				0.75
White	527 (88.1)	398 (88.2)	129 (87.8)		212 (86.2)	104 (84.6)	108 (87.8)	
Black	22 (3.7)	18 (4.0)	4 (2.7)		8 (3.3)	5 (4.1)	3 (2.4)	
Other	49 (8.2)	35 (7.8)	14 (9.5)		26 (10.6)	14 (11.4)	12 (9.8)	
Marital status				0.47				>0.99
Unmarried	156 (26.1)	121 (26.8)	35 (23.8)		60 (24.4)	30 (24.4)	30 (24.4)	

Married	442 (73.9)	330 (73.2)	112 (76.2)		186 (75.6)	93 (75.6)	93 (75.6)	
T stage				<0.001				0.80
T1	394 (65.9)	332 (73.6)	62 (42.2)		120 (48.8)	59 (48)	61 (49.6)	
T2	204 (34.1)	119 (26.4)	85 (57.8)		126 (51.2)	64 (52)	62 (50.4)	
Grade				0.006				0.75
I	77 (12.9)	68 (15.1)	9 (6.1)		21 (8.5)	13 (10.6)	8 (6.5)	
II	261 (43.6)	195 (43.2)	66 (44.9)		114 (46.3)	58 (47.2)	56 (45.5)	
III	225 (37.6)	167 (37.0)	58 (39.5)		96 (39.0)	46 (37.4)	50 (40.7)	
IV	7 (1.2)	5 (1.1)	2 (1.4)		3 (1.2)	1 (0.8)	2 (1.6)	
Unknown	28 (4.7)	16 (3.5)	12 (8.2)		12 (4.9)	5 (4.1)	7 (5.7)	
Tumor size				<0.001				0.91
>2 cm	199 (33.3)	162 (35.9)	37 (25.2)		64 (26.0)	32 (26)	32 (26)	
≥2, <4 cm	196 (32.8)	162 (35.9)	34 (23.1)		72 (29.3)	38 (30.9)	34 (27.6)	
≥4, <6 cm	61 (10.2)	43 (9.5)	18 (12.2)		30 (12.2)	13 (10.6)	17 (13.8)	
≥6 cm	37 (6.2)	22 (4.9)	15 (10.2)		26 (10.6)	14 (11.4)	12 (9.8)	
Unknown	105 (17.6)	62 (13.7)	43 (29.3)		54 (22.0)	26 (21.1)	28 (22.8)	
Surgical type				0.005				0.29
TG	162 (27.1)	109 (24.2)	53 (36.1)		86 (35.0)	47 (38.2)	39 (31.7)	
PG	436 (72.9)	342 (75.8)	94 (63.9)		160 (65.0)	76 (61.8)	84 (68.3)	
ELN	15.2±9.8	15.1±10.1	15.4±9.2	0.77	15.3±8.6	15.4±8.9	15.2±8.4	0.84

Data are presented as n (%) or mean ± standard deviation. AEG, adenocarcinoma of the esophagogastric junction; ELN, examined lymph nodes; NS, Neoadjuvant-based therapy combined with surgery; PG, proximal gastrectomy; PSM, propensity score matching; SA, surgery alone; TG, total gastrectomy; T, tumor.

Table S3 Baseline characteristics of patients with locally advanced Siewert type II AEG

Characteristics	Unadjusted				PSM			
	Total (n=1,249)	SA (n=337)	NS (n=912)	P	Total (n=470)	SA (n=235)	NS (n=235)	P
Age, years	63.1±11.3	69.9±10.9	60.6±10.4	<0.001	64.8±10.4	66.2±10.6	63.3±9.9	0.002

Sex				<0.001				0.28
Male	1,029 (82.4)	245 (72.7)	784 (86.0)		387 (82.3)	189 (80.4)	198 (84.3)	
Female	220 (17.6)	92 (27.3)	128 (14.0)		83 (17.7)	46 (19.6)	37 (15.7)	
Race				0.003				0.61
White	1,094 (87.6)	278 (82.5)	816 (89.5)		405 (86.2)	201 (85.5)	204 (86.8)	
Black	58 (4.6)	24 (7.1)	34 (3.7)		29 (6.2)	17 (7.2)	12 (5.1)	
Other	97 (7.8)	35 (10.4)	62 (6.8)		36 (7.7)	17 (7.2)	19 (8.1)	
Marital status				<0.001				0.48
Unmarried	358 (28.7)	121 (35.9)	237 (26.0)		141 (30.0)	67 (28.5)	74 (31.5)	
Married	891 (71.3)	216 (64.1)	675 (74.0)		329 (70.0)	168 (71.5)	161 (68.5)	
T stage				<0.001				<0.001
T1	69 (5.5)	30 (8.9)	39 (4.3)		56 (11.9)	20 (8.5)	36 (15.3)	
T2	359 (28.7)	164 (48.7)	195 (21.4)		254 (54.0)	89 (37.9)	165 (70.2)	
T3	738 (59.1)	118 (35.0)	620 (68.0)		128 (27.2)	106 (45.1)	22 (9.4)	
T4	83 (6.6)	25 (7.4)	58 (6.4)		32 (6.8)	20 (8.5)	12 (5.1)	
N stage				0.02				<0.001
N0	198 (15.9)	41 (12.2)	157 (17.2)		43 (9.1)	34 (14.5)	9 (3.8)	
N1	696 (55.7)	186 (55.2)	510 (55.9)		290 (61.7)	129 (54.9)	161 (68.5)	
N2	253 (20.3)	72 (21.4)	181 (19.8)		92 (19.6)	48 (20.4)	44 (18.7)	
N3	102 (8.2)	38 (11.3)	64 (7.0)		45 (9.6)	24 (10.2)	21 (8.9)	
Grade				0.009				0.40
I	49 (3.9)	10 (3.0)	39 (4.3)		17 (3.6)	7 (3.0)	10 (4.3)	
II	369 (29.5)	95 (28.2)	274 (30.0)		136 (28.9)	71 (30.2)	65 (27.7)	
III	731 (58.5)	217 (64.4)	514 (56.4)		285 (60.6)	144 (61.3)	141 (60.0)	
IV	27 (2.2)	7 (2.1)	20 (2.2)		8 (1.7)	5 (2.1)	3 (1.3)	
Unknown	73 (5.8)	8 (2.4)	65 (7.1)		24 (5.1)	8 (3.4)	16 (6.8)	

Tumor size				<0.001				<0.001
>2 cm	84 (6.7)	18 (5.3)	66 (7.2)		35 (7.4)	12 (5.1)	23 (9.8)	
≥2, <4 cm	340 (27.2)	100 (29.7)	240 (26.3)		138 (29.4)	73 (31.1)	65 (27.7)	
≥4, <6 cm	339 (27.1)	107 (31.8)	232 (25.4)		136 (28.9)	77 (32.8)	59 (25.1)	
≥6 cm	272 (21.8)	97 (28.8)	175 (19.2)		103 (21.9)	58 (24.7)	45 (19.1)	
Unknown	214 (17.1)	15 (4.5)	199 (21.8)		58 (12.3)	15 (6.4)	43 (18.3)	
Surgical type				0.25				0.92
TG	360 (28.8)	89 (26.4)	271 (29.7)		123 (26.2)	62 (26.4)	61 (26.0)	
PG	889 (71.2)	248 (73.6)	641 (70.3)		347 (73.8)	173 (73.6)	174 (74.0)	
ELN	17.6±11.3	16.8±11.1	17.8±11.4	0.17	15.0 (9.0–23.0)	15.0 (9.0–23.0)	15.0 (10.0–23.5)	0.32

Data are presented as n (%), median (interquartile range) or mean ± standard deviation. AEG, adenocarcinoma of the esophagogastric junction; ELN, examined lymph nodes; N, node; NS, neoadjuvant-based therapy combined with surgery; PG, proximal gastrectomy; PSM, propensity score matching; SA, surgery alone; TG, total gastrectomy; T, tumor.

Table S4 Baseline characteristics of patients with locally advanced Siewert type II AEG receiving neoadjuvant therapy

Characteristics	Unadjusted				PSM			
	Total (n=912)	NO (n=736)	PT (n=176)	P	Total (n=336)	NO (n=168)	PT (n=168)	P
Age, years	60.6±10.4	60.9±10.2	59.2±11.1	0.06	59.3±11.2	59.5±11.4	59.1±11.1	0.76
Sex				0.08				>0.99
Male	784 (86.0)	640 (87.0)	144 (81.8)		274 (81.5)	137 (81.5)	137 (81.5)	
Female	128 (14.0)	96 (13.0)	32 (18.2)		62 (18.5)	31 (18.5)	31 (18.5)	
Race				0.01				0.77
White	816 (89.5)	669 (90.9)	147 (83.5)		282 (83.9)	139 (82.7)	143 (85.1)	
Black	34 (3.7)	22 (3.0)	12 (6.8)		21 (6.2)	12 (7.1)	9 (5.4)	
Other	62 (6.8)	45 (6.1)	17 (9.7)		33 (9.8)	17 (10.1)	16 (9.5)	
Marital status				0.17				0.33

Unmarried	237 (26.0)	184 (25.0)	53 (30.1)		94 (28.0)	43 (25.6)	51 (30.4)	
Married	675 (74.0)	552 (75.0)	123 (69.9)		242 (72.0)	125 (74.4)	117 (69.6)	
T stage				0.26				0.99
T1	39 (4.3)	29 (3.9)	10 (5.7)		19 (5.7)	9 (5.4)	10 (6.0)	
T2	195 (21.4)	166 (22.6)	29 (16.5)		59 (17.6)	30 (17.9)	29 (17.3)	
T3	620 (68.0)	496 (67.4)	124 (70.5)		235 (69.9)	118 (70.2)	117 (69.6)	
T4	58 (6.4)	45 (6.1)	13 (7.4)		23 (6.8)	11 (6.5)	12 (7.1)	
N stage				<0.001				0.55
N0	157 (17.2)	138 (18.8)	19 (10.8)		44 (13.1)	25 (14.9)	19 (11.3)	
N1	510 (55.9)	422 (57.3)	88 (50.0)		165 (49.1)	77 (45.8)	88 (52.4)	
N2	181 (19.8)	137 (18.6)	44 (25.0)		84 (25.0)	42 (25.0)	42 (25.0)	
N3	64 (7.0)	39 (5.3)	25 (14.2)		43 (12.8)	24 (14.3)	19 (11.3)	
Grade				0.051				0.50
I	39 (4.3)	33 (4.5)	6 (3.4)		14 (4.2)	8 (4.8)	6 (3.6)	
II	274 (30.0)	230 (31.2)	44 (25.0)		83 (24.7)	39 (23.2)	44 (26.2)	
III	514 (56.4)	401 (54.5)	113 (64.2)		213 (63.4)	108 (64.3)	105 (62.5)	
IV	20 (2.2)	14 (1.9)	6 (3.4)		8 (2.4)	2 (1.2)	6 (3.6)	
Unknown	65 (7.1)	58 (7.9)	7 (4.0)		18 (5.4)	11 (6.5)	7 (4.2)	
Tumor size				0.10				0.97
>2 cm	66 (7.2)	50 (6.8)	16 (9.1)		29 (8.6)	14 (8.3)	15 (8.9)	
≥2, <4 cm	240 (26.3)	205 (27.9)	35 (19.9)		73 (21.7)	38 (22.6)	35 (20.8)	
≥4, <6 cm	232 (25.4)	182 (24.7)	50 (28.4)		97 (28.9)	48 (28.6)	49 (29.2)	
≥6 cm	175 (19.2)	134 (18.2)	41 (23.3)		77 (22.9)	40 (23.8)	37 (22.0)	
Unknown	199 (21.8)	165 (22.4)	34 (19.3)		60 (17.9)	28 (16.7)	32 (19.0)	
Surgical type				0.03				0.50
TG	271 (29.7)	207 (28.1)	64 (36.4)		124 (36.9)	65 (38.7)	59 (35.1)	
PG	641 (70.3)	529 (71.9)	112 (63.6)		212 (63.1)	103 (61.3)	109 (64.9)	
ELN	17.8±11.4	17.2±11.0	20.5±12.6	<0.001	20.4±12.2	20.6±12.2	20.1±12.3	0.76

Data are presented as n (%) or mean ± standard deviation. AEG, adenocarcinoma of the esophagogastric junction; ELN, examined lymph nodes;

N, node; NO, Neoadjuvant only therapy; PG, proximal gastrectomy; PSM, propensity score matching; PT, Perioperative therapy; TG, total gastrectomy; T, tumor.

Table S5 Multivariable Cox regression analysis before and after PSM in patients with early-stage Siewert type II AEG

Characteristics	Before PSM		After PSM	
	OS HR (95% CI)	P	OS HR (95% CI)	P
Treatment modality				
SA	Reference		Reference	
NS				
Model I	1.45 (1.14–1.83)	0.002	1.36 (0.99–1.88)	0.06
Model II	1.65 (1.30–2.10)	<0.001	1.35 (0.98–1.87)	0.07
Model III	1.31 (1.01–1.70)	0.04	1.31 (0.94–1.83)	0.11

Model I: unadjusted. Model II: adjusted for age, sex, race, and marital status. Model III: adjusted for age, sex, race, marital status, T stage, grade, tumor size, surgical type, and ELN. CI, confidence interval; ELN, examined lymph nodes; HR, hazard ratio; NS, neoadjuvant-based therapy combined with surgery; OS, overall survival; PSM, propensity score matching; SA, surgery alone.

Table S6 Multivariable Cox regression analysis before and after PSM in patients with locally advanced Siewert type II AEG

Characteristics	Before PSM		After PSM	
	OS HR (95% CI)	P	OS HR (95% CI)	P
Treatment modality				
SA	Reference		Reference	
NS				
Model I	0.49 (0.43–0.56)	<0.001	0.61 (0.50–0.74)	<0.001
Model II	0.53 (0.46–0.61)	<0.001	0.62 (0.50–0.75)	<0.001
Model III	0.53 (0.45–0.62)	<0.001	0.60 (0.48–0.75)	<0.001

Model I: unadjusted. Model II: adjusted for age, sex, race, and marital status. Model III: adjusted for age, sex, race, marital status, T stage, N stage, grade, tumor size, surgical type, and ELN. CI, confidence interval; ELN, examined lymph nodes; HR, hazard ratio; NS, Neoadjuvant-based therapy combined with surgery; N, node; OS, overall survival; PSM, propensity score matching; SA, surgery alone.

Table S7 Multivariable Cox regression analysis before and after PSM in patients with locally advanced Siewert type II AEG receiving neoadjuvant therapy

Characteristics	Before PSM		After PSM	
	OS HR (95% CI)	P	OS HR (95% CI)	P
Treatment modality				
NO	Reference		Reference	
PT				
Model I	1.08 (0.89–1.30)	0.45	1.02 (0.80–1.31)	0.87
Model II	1.11 (0.92–1.34)	0.29	0.97 (0.76–1.25)	0.84
Model III	1.00 (0.82–1.22)	0.97	0.97 (0.75–1.26)	0.84

Model I: unadjusted. Model II: adjusted for age, sex, race, and marital status. Model III: adjusted for age, sex, race, marital status, T stage, N stage, grade, tumor size, surgical type, and ELN. CI, confidence interval; ELN, examined lymph nodes; HR, hazard ratio; NO, Neoadjuvant only therapy; N, node; OS, overall survival; PSM, propensity score matching; PT, Perioperative therapy.

Table S8 Baseline characteristics of patients with early-stage Siewert type II AEG in the training and testing sets

Characteristics	Total (n=598)	Training (n=419)	Testing (n=179)	P
Age, years	65.2±10.9	65.0±11.1	65.7±10.6	0.47
Sex				0.47
Male	470 (78.6)	326 (77.8)	144 (80.4)	
Female	128 (21.4)	93 (22.2)	35 (19.6)	
Race				0.26
White	527 (88.1)	373 (89.0)	154 (86.0)	
Black	22 (3.7)	12 (2.9)	10 (5.6)	
Other	49 (8.2)	34 (8.1)	15 (8.4)	
Marital status				0.64
Unmarried	156 (26.1)	107 (25.5)	49 (27.4)	
Married	442 (73.9)	312 (74.5)	130 (72.6)	
T stage				0.09

T1	394 (65.9)	267 (63.7)	127 (70.9)	0.29
T2	204 (34.1)	152 (36.3)	52 (29.1)	
Grade				
I	77 (12.9)	61 (14.6)	16 (8.9)	
II	261 (43.6)	176 (42.0)	85 (47.5)	
III	225 (37.6)	157 (37.5)	68 (38.0)	0.91
IV	7 (1.2)	4 (1.0)	3 (1.7)	
Unknown	28 (4.7)	16 (3.5)	12 (8.2)	
Tumor size				
>2 cm	199 (33.3)	140 (33.4)	59 (33.0)	0.13
≥2, <4 cm	196 (32.8)	138 (32.9)	58 (32.4)	
≥4, <6 cm	61 (10.2)	45 (10.7)	16 (8.9)	
≥6 cm	37 (6.2)	26 (6.2)	11 (6.1)	
Unknown	105 (17.6)	70 (16.7)	35 (19.6)	
Surgical type				0.53
TG	162 (27.1)	106 (25.3)	56 (31.3)	
PG	436 (72.9)	313 (74.7)	123 (68.7)	0.07
Treatment modality				
SA	451 (75.4)	313 (74.7)	138 (77.1)	0.07
NS	147 (24.6)	106 (25.3)	41 (22.9)	
ELN	15.2±9.8	14.7±9.8	16.3±10.0	

Data are presented as n (%) or mean ± standard deviation. AEG, adenocarcinoma of the esophagogastric junction; ELN, examined lymph nodes; NS, neoadjuvant-based therapy combined with surgery; PG, proximal gastrectomy; SA, surgery alone; TG, total gastrectomy; T, tumor.

Table S9 Baseline characteristics of patients with locally advanced Siewert type II AEG in the training and testing sets

Characteristics	Total (n=1,249)	Training (n=875)	Testing (n=374)	P
Age, years	63.1±11.3	63.3±11.3	62.5±11.4	0.26
Sex				0.76

Male	1,029 (82.4)	719 (82.2)	310 (82.9)	0.50
Female	220 (17.6)	156 (17.8)	64 (17.1)	
Race				0.50
White	1,094 (87.6)	765 (87.4)	329 (88.0)	
Black	58 (4.6)	38 (4.3)	20 (5.3)	
Other	97 (7.8)	72 (8.2)	25 (6.7)	
Marital status				0.48
Unmarried	358 (28.7)	256 (29.3)	102 (27.3)	
Married	891 (71.3)	619 (70.7)	272 (72.7)	
T stage				0.97
T1	69 (5.5)	47 (5.4)	22 (5.9)	
T2	359 (28.7)	250 (28.6)	109 (29.1)	
T3	738 (59.1)	519 (59.3)	219 (58.6)	
T4	83 (6.6)	59 (6.7)	24 (6.4)	
N stage				0.64
N0	198 (15.9)	144 (16.5)	54 (14.4)	
N1	696 (55.7)	479 (54.7)	217 (58.0)	
N2	253 (20.3)	182 (20.8)	71 (19.0)	
N3	102 (8.2)	70 (8.0)	32 (8.6)	
Grade				0.51
I	49 (3.9)	37 (4.2)	12 (3.2)	
II	369 (29.5)	259 (29.6)	110 (29.4)	
III	731 (58.5)	508 (58.1)	223 (59.6)	
IV	27 (2.2)	16 (1.8)	11 (2.9)	
Unknown	73 (5.8)	55 (6.3)	18 (4.8)	
Tumor size				0.18
>2 cm	84 (6.7)	55 (6.3)	29 (7.8)	
≥2, <4 cm	340 (27.2)	239 (27.3)	101 (27.0)	
≥4, <6 cm	339 (27.1)	227 (25.9)	112 (29.9)	

≥6 cm	272 (21.8)	191 (21.8)	81 (21.7)	
Unknown	214 (17.1)	163 (18.6)	51 (13.6)	
Surgical type				0.43
TG	360 (28.8)	258 (29.5)	102 (27.3)	
PG	889 (71.2)	617 (70.5)	272 (72.7)	
Treatment modality				0.79
SA	337 (27.0)	238 (27.2)	99 (26.5)	
NS	912 (73.0)	637 (72.8)	275 (73.5)	
ELN	17.6±11.3	17.4±11.1	17.9±11.8	0.42

Data are presented as n (%) or mean ± standard deviation. AEG, adenocarcinoma of the esophagogastric junction; ELN, examined lymph nodes; NS, Neoadjuvant-based therapy combined with surgery; PG, proximal gastrectomy; SA, surgery alone; TG, total gastrectomy; T, tumor.